Dmitry Kovalchuk / Shutterstock.com
While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.
As the COVID-19 pandemic reaches its two-year anniversary, the world’s battle against the virus continues. But while the world’s attention is (rightly) focused on variants, vaccines and other virus mitigation tools, there are less-reported seismic shifts in the global approach to IP among private companies and governments reacting to COVID-19.
Chief among these is a global push to waive certain provisions of the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), most significantly a three-year waiver from enforcing IP that concerns the “prevention, containment and treatment of COVID-19”.
Support for the waiver has gradually gained momentum since it was initially proposed by India and South Africa in October 2020, including from the US and 60 other countries across various iterations of the draft waiver. Some opposition to the concept of a waiver, however, remains—especially in the UK, Germany and the EU (the EU being a WTO member in its own right).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Alston & Bird, COVID-19, vaccine, IP waiver, innovation, WTO, TRIPS, compulsory licence, Joe Biden, Donald Trump, Johnson & Johnson, Pfizer, Moderna